These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
902 related articles for article (PubMed ID: 23194489)
1. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489 [TBL] [Abstract][Full Text] [Related]
2. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071 [TBL] [Abstract][Full Text] [Related]
3. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH; Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M; Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M; Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949 [TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293 [TBL] [Abstract][Full Text] [Related]
8. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825 [TBL] [Abstract][Full Text] [Related]
9. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Mountantonakis SE; Grau-Sepulveda MV; Bhatt DL; Hernandez AF; Peterson ED; Fonarow GC Circ Heart Fail; 2012 Mar; 5(2):191-201. PubMed ID: 22361078 [TBL] [Abstract][Full Text] [Related]
10. Incidence, risk factors, and clinical outcomes of atrial fibrillation and atrial flutter after heart transplantation. Dasari TW; Pavlovic-Surjancev B; Patel N; Williams AA; Ezidinma P; Rupani A; Sinacore JL; Heroux AL Am J Cardiol; 2010 Sep; 106(5):737-41. PubMed ID: 20723655 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M; Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555 [TBL] [Abstract][Full Text] [Related]
12. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. Khitri AR; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Kowey PR J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925 [TBL] [Abstract][Full Text] [Related]
13. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M; Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107 [TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D; Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522 [TBL] [Abstract][Full Text] [Related]
15. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. Patel RB; Vaduganathan M; Rikhi A; Chakraborty H; Greene SJ; Hernandez AF; Felker GM; Redfield MM; Butler J; Shah SJ JACC Heart Fail; 2019 Jan; 7(1):47-55. PubMed ID: 30409707 [TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A; J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Kalscheur MM; Saxon LA; Lee BK; Steinberg JS; Mei C; Buhr KA; DeMets DL; Bristow MR; Singh SN Heart Rhythm; 2017 Jun; 14(6):858-865. PubMed ID: 28323173 [TBL] [Abstract][Full Text] [Related]
18. Atrial flutter or fibrillation is the most frequent and life-threatening arrhythmia in myotonic dystrophy. Brembilla-Perrot B; Schwartz J; Huttin O; Frikha Z; Sellal JM; Sadoul N; Blangy H; Olivier A; Louis S; Kaminsky P Pacing Clin Electrophysiol; 2014 Mar; 37(3):329-35. PubMed ID: 24117873 [TBL] [Abstract][Full Text] [Related]
19. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Lip GY Eur J Heart Fail; 2013 Apr; 15(4):415-24. PubMed ID: 23302606 [TBL] [Abstract][Full Text] [Related]
20. Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. Amin AN; Jhaveri M; Lin J J Med Econ; 2012; 15(3):548-55. PubMed ID: 22352988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]